Thrivent Financial for Lutherans Lowers Stake in Pediatrix Medical Group, Inc. (NYSE:MD)

Thrivent Financial for Lutherans decreased its stake in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 3.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,507 shares of the company’s stock after selling 2,364 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Pediatrix Medical Group were worth $771,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. nVerses Capital LLC purchased a new stake in shares of Pediatrix Medical Group in the second quarter valued at approximately $31,000. Innealta Capital LLC purchased a new stake in shares of Pediatrix Medical Group during the 2nd quarter worth about $33,000. Nisa Investment Advisors LLC raised its position in Pediatrix Medical Group by 47.2% in the second quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock valued at $36,000 after purchasing an additional 1,524 shares during the period. Canada Pension Plan Investment Board purchased a new stake in shares of Pediatrix Medical Group during the second quarter valued at approximately $72,000. Finally, CWM LLC boosted its holdings in Pediatrix Medical Group by 134.0% in the third quarter. CWM LLC now owns 6,427 shares of the company’s stock valued at $74,000 after purchasing an additional 3,681 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Performance

MD opened at $14.82 on Wednesday. The company has a current ratio of 1.42, a quick ratio of 1.42 and a debt-to-equity ratio of 0.83. The firm’s fifty day moving average price is $13.42 and its two-hundred day moving average price is $10.33. Pediatrix Medical Group, Inc. has a fifty-two week low of $6.62 and a fifty-two week high of $16.41.

Pediatrix Medical Group (NYSE:MD) last posted its earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. The business had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.29 earnings per share. On average, equities analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 EPS for the current year.

Insider Transactions at Pediatrix Medical Group

In other news, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the completion of the sale, the executive vice president now owns 135,810 shares of the company’s stock, valued at approximately $2,172,960. This trade represents a 5.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now directly owns 138,683 shares in the company, valued at $2,128,784.05. The trade was a 16.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on MD. Truist Financial upped their target price on Pediatrix Medical Group from $13.00 to $16.00 and gave the company a “hold” rating in a report on Monday, November 4th. StockNews.com cut Pediatrix Medical Group from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Mizuho upped their target price on Pediatrix Medical Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Jefferies Financial Group raised their target price on Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, UBS Group increased their price objective on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Five equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $16.10.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.